« Previous Next » American Heart Journal
Volume 156, Issue 6 , Pages 1154.e1-1154.e8 , December 2008

Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension

Claudio Napoli, MD, PhD, MBEth, FACA
- Department of General Pathology and Excellence Research Center on Cardiovascular Diseases, and Microbiology Section, 1st School of Medicine, II University of Naples, Naples, Italy
- IRCCS, Multimedica, Milan, Italy
- Reprint requests: Professor Claudio Napoli, MD, PhD, MBEth, FACA, Department of General Pathology and Excellence Research Center on Cardiovascular Diseases, 1^st School of Medicine, II University of Naples; Complesso S. Andrea delle Dame; Via L. de Crecchio 7, Naples, 80138, Italy.
Giuseppe Bruzzese, MD
- Division of Cardiology-UTIC, Pellegrini Hospital, ASLNA1, Naples, Italy
Louis J. Ignarro, PhD
- Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA
Ettore Crimi, MD
- Department of Anesthesia and Critical Care, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Filomena de Nigris, BiolD, PhD
- Department of General Pathology and Excellence Research Center on Cardiovascular Diseases, and Microbiology Section, 1st School of Medicine, II University of Naples, Naples, Italy
Sharon Williams-Ignarro, MD
- Division of Anesthesiology and, David Geffen School of Medicine, University of California, Los Angeles, CA
Sabina Libardi, BS
- IRCCS, Multimedica, Milan, Italy
Linda Sommese, BiolD
- Department of General Pathology and Excellence Research Center on Cardiovascular Diseases, and Microbiology Section, 1st School of Medicine, II University of Naples, Naples, Italy
Carmela Fiorito, BS
- IRCCS, Multimedica, Milan, Italy
Francesco P. Mancini, MD, PhD
- Department of Biological and Environmental Sciences, University of Sannio, Benevento, Italy
Francesco Cacciatore, MD, PhD, MPH
- Fondazione Salvatore Maugeri, IRCCS, Telese Terme (BN), Italy
Antonio Liguori, MD
- Division of Cardiology-UTIC, Pellegrini Hospital, ASLNA1, Naples, Italy

Received 24 June 2008 ,Accepted 10 September 2008.

A, The IMT determinations in zofenopril- and enalapril-treated patients at baseline and after 1, 3, and 5 years since the beginning of the study. B, Vascular lumen diameter determinations in zofenopri

A, The IMT determinations in zofenopril- and enalapril-treated patients at baseline and after 1, 3, and 5 years since the beginning of the study. B, Vascular lumen diameter determinations in zofenopril- and enalapril-treated patients at baseline and after 1, 3, and 5 years since the beginning of the study. ⁎P < .05 or °P < .01 by ANOVA versus enalapril.
- Full-Size Image
- Download to PowerPoint
Levels of the isoprostane 8-iso-PGF2α at baseline and after 1 and 5 years of treatment with 20 mg/d of enalapril or 30 mg/d of zofenopril. ⁎P < .01 vs respective baseline; °P < .05 vs enalapril.

Levels of the isoprostane 8-iso-PGF2α at baseline and after 1 and 5 years of treatment with 20 mg/d of enalapril or 30 mg/d of zofenopril. ⁎P < .01 vs respective baseline; °P < .05 vs enalapril.
- Full-Size Image
- Download to PowerPoint

Presented in abstract form at the Symposium “Current role of angiotensin converting enzyme-inhibitors in high-risk patients,” European Society of Cardiology, September 1, 2003, Wien (Austria); at the Plenary Session on ACE-Inhibition, 65° National Congress of the Italian Society of Cardiology, December 13, 2004, Rome, Italy; at the Plenary Session on “The renin angiotensin system and oxidative stress,” 4° International Forum on Angiotensin II Receptor Antagonism, January 28, 2005, Monte Carlo, Monaco; and at the Annual Meeting of European Society of Atherosclerosis, June 10, 2007, Helsinki, Finland.

PII: S0002-8703(08)00791-6

doi: 10.1016/j.ahj.2008.09.006

« Previous Next » American Heart Journal
Volume 156, Issue 6 , Pages 1154.e1-1154.e8 , December 2008